KLK3 and posterior cortical atrophy: Generally, patients with PCa are classified into either a low, intermediate, or high risk group based on their prostate-specific Antigen (PSA) level, pathological assessment/Gleason Score (GS) [5,6], and clinical stage (i.e., T stage) [7].